Responses
Gastroenterology and hepatology
Protocol
Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.